Aarti Drugs Limited (NSE: AARTIDRUGS) stock breaks out, moving up 5% intraday to ₹444.0, clearing its 6M resistance trendline.
Aarti Drugs Limited (NSE: AARTIDRUGS) reports Q1 FY27 revenue up 19% YoY, EBITDA margin expands 120 bps, driven by growth in API & Specialty Chemicals.
Aarti Drugs Limited (NSE: AARTIDRUGS) shows pressure after breakout, falling 5% intraday to ₹404.5. This retracement follows clearing 6M resistance.